Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03922880
Title Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

melanoma

uveal melanoma

Therapies

ADI-PEG 20 + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.